Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Oct 14

PMID 37835519

Authors

Anna Lisa Cammarota

Antonia Falco

Anna Basile

Carlo Molino

Massimiliano Chetta

Gianni DAngelo

Liberato Marzullo

Margot De Marco

Maria Caterina Turco

Alessandra Rosati

Affiliations

Soon will be listed here.

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is a ravaging disease with a poor prognosis, requiring a more detailed understanding of its biology to foster the development of effective therapies. The unsatisfactory results of treatments targeting cell proliferation and its related mechanisms suggest a shift in focus towards the inflammatory tumor microenvironment (TME). Here, we discuss the role of cancer-secreted proteins in the complex TME tumor-stroma crosstalk, shedding lights on druggable molecular targets for the development of innovative, safer and more efficient therapeutic strategies.

Citing Articles

Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone.

Yagi T, Kagawa S, Nogi S, Taniguchi A, Yoshimoto M, Suemori K Cancer Immunol Immunother. 2025; 74(3):96.

PMID: 39904796 PMC: 11794937. DOI: 10.1007/s00262-025-03946-z.

References

Niu X, Yin L, Yang X, Yang Y, Gu Y, Sun Y . Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer. Cancer Sci. 2022; 113(4):1140-1153. PMC: 8990718. DOI: 10.1111/cas.15287. View

Singhi A, George B, Greenbowe J, Chung J, Suh J, Maitra A . Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019; 156(8):2242-2253.e4. DOI: 10.1053/j.gastro.2019.02.037. View

Mamdani H, Matosevic S, Khalid A, Durm G, Jalal S . Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022; 13:823618. PMC: 8864096. DOI: 10.3389/fimmu.2022.823618. View

Menzies-Gow A, Ying S, Sabroe I, Stubbs V, Soler D, Williams T . Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002; 169(5):2712-8. DOI: 10.4049/jimmunol.169.5.2712. View

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

Yi N, Zhao X, Ji J, Xu M, Jiao Y, Qian T . Serum galectin-3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. J Cell Mol Med. 2020; 24(19):11583-11591. PMC: 7576229. DOI: 10.1111/jcmm.15775. View

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Singh R, Mohammad J, Orr M, Reindl K . Glutathione S-Transferase pi-1 Knockdown Reduces Pancreatic Ductal Adenocarcinoma Growth by Activating Oxidative Stress Response Pathways. Cancers (Basel). 2020; 12(6). PMC: 7352757. DOI: 10.3390/cancers12061501. View

Principe D, Underwood P, Korc M, Trevino J, Munshi H, Rana A . The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol. 2021; 11:688377. PMC: 8319847. DOI: 10.3389/fonc.2021.688377. View

10.

Dufrusine B, Damiani V, Capone E, Pieragostino D, Dainese E, De Marco M . BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration. J Cell Biochem. 2021; 123(1):65-76. PMC: 9297949. DOI: 10.1002/jcb.30172. View

11.

Khalaf N, El-Serag H, Abrams H, Thrift A . Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin Gastroenterol Hepatol. 2020; 19(5):876-884. PMC: 8559554. DOI: 10.1016/j.cgh.2020.02.054. View

12.

Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A . Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers (Basel). 2022; 14(10). PMC: 9139656. DOI: 10.3390/cancers14102429. View

13.

de Oliveira G, Paccielli Freire P, Cury S, de Moraes D, Oliveira J, Dal-Pai-Silva M . An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020; 12(3). PMC: 7140071. DOI: 10.3390/cancers12030716. View

14.

Li Y, Xiang S, Pan W, Wang J, Zhan H, Liu S . Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. 2023; 13:1166860. PMC: 10090519. DOI: 10.3389/fonc.2023.1166860. View

15.

De Morais J, Zelanis A . Bioinformatic reanalysis of public proteomics data reveals that nuclear proteins are recurrent in cancer secretomes. Traffic. 2021; 23(2):98-108. DOI: 10.1111/tra.12827. View

16.

Xelwa N, Candy G, Devar J, Omoshoro-Jones J, Smith M, Nweke E . Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance. Front Oncol. 2021; 11:683788. PMC: 8236623. DOI: 10.3389/fonc.2021.683788. View

17.

Principe M, Borgoni S, Cascione M, Chattaragada M, Ferri-Borgogno S, Capello M . Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol. 2017; 10(1):16. PMC: 5237223. DOI: 10.1186/s13045-016-0385-8. View

18.

Kindler H, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H . Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28(22):3617-22. PMC: 2917317. DOI: 10.1200/JCO.2010.28.1386. View

19.

Wang M, Fer N, Galeas J, Collisson E, Kim S, Sharib J . Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019; 10(1):3055. PMC: 6624260. DOI: 10.1038/s41467-019-11044-9. View

20.

Firpo M, Boucher K, Bleicher J, Khanderao G, Rosati A, Poruk K . Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO Clin Cancer Inform. 2023; 7:e2200160. PMC: 10530881. DOI: 10.1200/CCI.22.00160. View